Payment overview · 2025
General Payments
$75.34
2 reported records · 2 companies
Healthcare provider profile · identity verified
David Badillo-Torres, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · AGUADILLA, PUERTO RICO · NPI 1982995593
Verified facts
What the public records show
CMS Open Payments records show David Badillo-Torres, M.D. received $75.34 in general payments during 2025 across 2 reported records.
REVANCE THERAPEUTICS, INC. accounted for 67.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $50.60 | 67.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.74 | 32.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $75.34 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DAXI Normalized: daxi |
Drug | REVANCE THERAPEUTICS, INC. | $50.60 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $24.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
121 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 716 | 258 |
| Omeprazole | Omeprazole | 615 | 120 |
| Famotidine | Famotidine | 527 | 128 |
| Gabapentin | Gabapentin | 492 | 181 |
| Losartan Potassium | Losartan Potassium | 452 | 162 |
| Levothyroxine Sodium | Levothyroxine Sodium | 432 | 145 |
| Alendronate Sodium | Alendronate Sodium | 405 | 128 |
| Metoprolol Succinate | Metoprolol Succinate | 393 | 138 |
| Simvastatin | Simvastatin | 367 | 123 |
| Glimepiride | Glimepiride | 352 | 114 |
| Lisinopril | Lisinopril | 334 | 104 |
| Clonazepam | Clonazepam | 314 | 52 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 290 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 285 | 99 |
| Metformin Hcl | Metformin Hcl | 273 | 105 |
| Pantoprazole Sodium | Pantoprazole Sodium | 259 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 254 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 232 | 85 |
| Diclofenac Sodium | Diclofenac Sodium | 217 | 95 |
| Tamsulosin Hcl | Tamsulosin Hcl | 201 | 79 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 194 | 43 |
| Synthroid | Levothyroxine Sodium | 189 | 58 |
| Dexamethasone | Dexamethasone | 163 | 119 |
| Prednisone | Prednisone | 156 | 113 |
| Montelukast Sodium | Montelukast Sodium | 138 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 133 | 35 |
| Alprazolam | Alprazolam | 130 | 21 |
| Farxiga | Dapagliflozin Propanediol | 121 | 28 |
| Latanoprost | Latanoprost | 116 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 114 | 45 |
| Irbesartan | Irbesartan | 112 | 39 |
| Eliquis | Apixaban | 110 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 110 | 42 |
| Doxazosin Mesylate | Doxazosin Mesylate | 106 | 47 |
| Trazodone Hcl | Trazodone Hcl | 106 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 34 |
| Azithromycin | Azithromycin | 102 | 85 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 102 | 36 |
| Carvedilol | Carvedilol | 97 | 39 |
| Nabumetone | Nabumetone | 94 | 44 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 93 | 24 |
| Metformin Hcl Er | Metformin Hcl | 92 | 34 |
| Temazepam | Temazepam | 92 | 14 |
| Lansoprazole | Lansoprazole | 90 | 12 |
| Finasteride | Finasteride | 86 | 36 |
| Glipizide | Glipizide | 85 | 28 |
| Meloxicam | Meloxicam | 85 | 38 |
| Ezetimibe | Ezetimibe | 83 | 30 |
| Furosemide | Furosemide | 83 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 83 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 79 | 29 |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 76 | 26 |
| Albuterol Sulfate | Albuterol Sulfate | 75 | 58 |
| Ibuprofen | Ibuprofen | 74 | 31 |
| Sure Comfort | Syringe-Needle,insulin,0.5 Ml | 74 | 17 |
| Xarelto | Rivaroxaban | 74 | 12 |
| Candesartan Cilexetil | Candesartan Cilexetil | 72 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 25 |
| Insulin Lispro | Insulin Lispro | 70 | 18 |
| Ketoconazole | Ketoconazole | 68 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 26 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 61 | 12 |
| Jentadueto | Linagliptin/Metformin Hcl | 61 | 11 |
| Lorazepam | Lorazepam | 61 | suppressed |
| Etodolac | Etodolac | 60 | 11 |
| Sertraline Hcl | Sertraline Hcl | 60 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | suppressed |
| Memantine Hcl | Memantine Hcl | 58 | 24 |
| Fluconazole | Fluconazole | 57 | 49 |
| Meclizine Hcl | Meclizine Hcl | 57 | 32 |
| Pregabalin | Pregabalin | 57 | 13 |
| Synjardy | Empagliflozin/Metformin Hcl | 55 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 54 | 20 |
| Atenolol | Atenolol | 51 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 20 |
| Enalapril Maleate | Enalapril Maleate | 48 | 20 |
| Nitroglycerin | Nitroglycerin | 48 | 18 |
| Pentoxifylline | Pentoxifylline | 48 | 20 |
| Glipizide Er | Glipizide | 44 | 17 |
| Jardiance | Empagliflozin | 44 | suppressed |
| Sure Comfort | Syringe And Needle,insulin,1ml | 44 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 40 | 17 |
| Risperidone | Risperidone | 39 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 39 | 13 |
| Timolol Maleate | Timolol Maleate | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 36 | suppressed |
| Levofloxacin | Levofloxacin | 36 | 35 |
| Nystatin | Nystatin | 36 | 32 |
| Methylprednisolone | Methylprednisolone | 35 | 32 |
| Phenobarbital | Phenobarbital | 35 | suppressed |
| Acarbose | Acarbose | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 32 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 30 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Advocate Syringes | Syringe-Needle,insulin,0.5 Ml | 29 | suppressed |
| Ibu | Ibuprofen | 29 | 13 |
| Nifedipine Er | Nifedipine | 29 | 12 |
| Galantamine Hbr | Galantamine Hbr | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 24 |
| Allopurinol | Allopurinol | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Humalog | Insulin Lispro | 24 | suppressed |
| Humulin R | Insulin Regular, Human | 24 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 20 |
| Tradjenta | Linagliptin | 23 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 22 | 11 |
| Ranolazine Er | Ranolazine | 22 | suppressed |
| Rivastigmine | Rivastigmine | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | 11 |
| Ciclopirox | Ciclopirox | 21 | 14 |
| Cilostazol | Cilostazol | 21 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 21 | 11 |
| Lovastatin | Lovastatin | 21 | suppressed |
| Acetic Acid | Acetic Acid | 20 | 17 |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Levoxyl | Levothyroxine Sodium | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Sure Comfort | Syring-Needl,disp,insul,0.3 Ml | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 18 | 14 |
| Lactulose | Lactulose | 18 | 14 |
| Procto-Med Hc | Hydrocortisone | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Advocate Syringes | Syring-Needl,disp,insul,0.3 Ml | 17 | suppressed |
| Advocate Syringes | Syringe And Needle,insulin,1ml | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 17 | 15 |
| Risedronate Sodium | Risedronate Sodium | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Cefadroxil | Cefadroxil | 14 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Insulin Glargine | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 11 |
| Diclofenac Epolamine | Diclofenac Epolamine | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $75.34 · 2 records | REVANCE THERAPEUTICS, INC. | AIRSUPRA, DAXI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error